Molecular Tumor Board: 58-year-old male with breast carcinoma and BRCA2 R3128* mutation

Though less common than in women, understanding male breast cancer and symptoms can lead to earlier detection and improved outcomes.

Join us in this molecular tumor board where we discussed a case of male breast cancer with molecular evolution in the BRCA2 gene associated with therapeutic resistance. We highlight the importance of both germline and somatic testing for treatment implications. Genomic testing at disease progression can be particularly helpful in identifying the complex mechanisms of treatment resistance, such as BRCA reversion mutations, to help inform treatment decisions.